Clinical Research Directory
Browse clinical research sites, groups, and studies.
Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology
Sponsor: University Hospital, Toulouse
Summary
This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.
Official title: Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes in Nulliparous Women After Assisted Reproductive Technology. APPART
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1164
Start Date
2023-08-02
Completion Date
2026-05
Last Updated
2024-01-22
Healthy Volunteers
No
Conditions
Interventions
Aspirin
Experimental drug administrated orally
Placebo
Treatment for the control group
Locations (21)
CHU Angers
Angers, France
CHU Bordeaux
Bordeaux, France
CHU Clermont-Ferrand
Clermont-Ferrand, France
CHU Dijon-Bourgogne
Dijon, France
CHU Lille
Lille, France
HCL - Groupement Hospitalier Est, Hôpital Femme Mère Enfant
Lyon, France
AP-HM Hôpital de la Conception
Marseille, France
AP-HM Hôpital Nord
Marseille, France
CHU Montpellier
Montpellier, France
CHRU Nancy
Nancy, France
CHU Nantes
Nantes, France
CHU Nîmes
Nîmes, France
Groupe hospitalier St Joseph
Paris, France
Hôpital Armand - Trousseau
Paris, France
Hôpital Cochin
Paris, France
CHI Poissy Saint Germain en Laye
Poissy, France
CHU Poitiers
Poitiers, France
CHU Rennes
Rennes, France
CHU Saint Etienne, Hôpital Nord
Saint-Etienne, France
CHU Strasbourg
Strasbourg, France
CHU Toulouse
Toulouse, France